Adagloxad Simolenin For Early-Stage Triple Negative Breast Cancer
Among breast cancer subtypes, triple nagative breast cancer (TNBC) exhibits the worst clinical outcome, with more than 30% of early-stage patients developing relapses during the first 2–3 years from diagnosis. Adagloxad simolenin, a first-in-class active immunotherapy in development for TNBC, may address this unmet medical need.
Adagloxad simolenin (formerly OBI-822) is exclusively licensed to OBI from Merck & Co. (Merck Sharp & Dohme, MSD). It is a conjugate of Globo H and keyhole limpet hemocyanin (KLH).
Two Phase I studies in relapsed prostate cancer and metastatic breast cancer patients, which were conducted by Memorial Sloan-Kettering Cancer Center (MSKCC), showed that adagloxad simolenin is very safe. It was also shown to induce a strong immune response against cancer cells.